Maneechote Chayodom, Kerdphoo Sasiwan, Jaiwongkam Thidarat, Chattipakorn Siriporn C, Chattipakorn Nipon
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.
Cardiovasc Drugs Ther. 2023 Feb;37(1):89-105. doi: 10.1007/s10557-021-07250-7. Epub 2021 Sep 13.
There is an increasing body of evidence to show that impairment in mitochondrial dynamics including excessive fission and insufficient fusion has been observed in the pre-diabetic condition. In pre-diabetic rats with cardiac ischemia-reperfusion (I/R) injury, acute treatment with a mitochondria fission inhibitor (Mdivi-1) and a fusion promoter (M1) showed cardioprotection. However, the potential preventive effects of chronic Mdivi-1 and M1 treatment in a pre-diabetic model of cardiac I/R have never been elucidated.
Male Wistar rats (n = 40) were fed with a high-fat diet (HFD) for 12 weeks to induce prediabetes. Then, all pre-diabetic rats received the following treatments daily via intraperitoneal injection for 2 weeks: (1) HFDV (Vehicle, 0.1% DMSO); (2) HFMdivi1 (Mdivi-1 1.2 mg/kg); (3) HFM1 (M1 2 mg/kg); and (4) HFCom (Mdivi-1 + M1). At the end of treatment protocols, all rats underwent 30 min of coronary artery ligation followed by reperfusion for 120 min.
Chronic Mdivi-1, M1, and the combined treatment showed markedly improved cardiac mitochondrial function and dynamic control, leading to a decrease in cardiac arrhythmias, myocardial cell death, and infarct size (49%, 42%, and 51% reduction for HFMdivi1, HFM1, and HFCom, respectively vs HFDV). All of these treatments improved cardiac function following cardiac I/R injury in pre-diabetic rats.
Chronic inhibition of mitochondrial fission and promotion of fusion exerted cardioprevention in prediabetes with cardiac I/R injury through the relief of cardiac mitochondrial dysfunction and dynamic alterations, and reduction in myocardial infarction, thus improving cardiac function.
越来越多的证据表明,在糖尿病前期状态下已观察到线粒体动力学受损,包括过度分裂和融合不足。在患有心脏缺血再灌注(I/R)损伤的糖尿病前期大鼠中,用线粒体分裂抑制剂(Mdivi-1)和融合促进剂(M1)进行急性治疗显示出心脏保护作用。然而,慢性给予Mdivi-1和M1对糖尿病前期心脏I/R模型的潜在预防作用尚未阐明。
雄性Wistar大鼠(n = 40)喂食高脂饮食(HFD)12周以诱导糖尿病前期。然后,所有糖尿病前期大鼠通过腹腔注射每天接受以下治疗,持续2周:(1)HFDV(溶剂,0.1%二甲基亚砜);(2)HFMdivi1(Mdivi-1 1.2mg/kg);(3)HFM1(M1 2mg/kg);和(4)HFCom(Mdivi-1 + M1)。在治疗方案结束时,所有大鼠进行30分钟冠状动脉结扎,然后再灌注120分钟。
慢性给予Mdivi-1、M1以及联合治疗均显示心脏线粒体功能和动态控制明显改善,导致心律失常、心肌细胞死亡和梗死面积减少(HFMdivi1、HFM1和HFCom分别比HFDV减少49%、42%和51%)。所有这些治疗均改善了糖尿病前期大鼠心脏I/R损伤后的心脏功能。
慢性抑制线粒体分裂和促进融合通过缓解心脏线粒体功能障碍和动态改变以及减少心肌梗死,从而改善心脏功能,对糖尿病前期合并心脏I/R损伤发挥心脏保护作用。